Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839

NCT02306811 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT02306811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02306811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2015
Completion date
July 31, 2016
Enrollment
62 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis